Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population

Simple item page
dc.contributor.authorZambrano-Huailla, Rommel
dc.contributor.authorGuedes, Laura
dc.contributor.authorStefano, Jose Tadeu
dc.contributor.authorde Souza, Arthur A. Arrais
dc.contributor.authorMarciano, Sebastian
dc.contributor.authorYvamoto, Erika
dc.contributor.authorMichalczuk, Matheus Truccolo
dc.contributor.authorVanni, Denise Siqueira
dc.contributor.authorRodriguez, Hernan
dc.contributor.authorCarrilho, Flair Jose
dc.contributor.authorAlvares-da-Silva, Mario Reis
dc.contributor.authorGadano, Adrian
dc.contributor.authorArrese, Marco
dc.contributor.authorMiranda, Adelina Lozano
dc.contributor.authorOliveira, Claudia P.
dc.date.accessioned2025-01-23T19:47:03Z
dc.date.available2025-01-23T19:47:03Z
dc.date.issued2020
dc.description.abstractIntroduction and aims: Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients.
dc.description.abstractMethods: Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis.
dc.description.abstractResults: The distribution of fibrosis stages among the sample population was as follows: F0 (45%), Fl (27%), F2 (8%), F3 (16%) and F4 (4%). Using modified thresholds, the areas under the ROC curves (AUROC) for Hepamet and FIB-4 (0.73 and 0.74, respectively) to detect significant fibrosis were higher than that of NFS (0.58). However, the AUROCs of the three scores were not significantly different in advanced fibrosis and cirrhosis. To exclude fibrosis, we calculated lower cutoffs than standard thresholds for Hepamet, FIB-4 and NFS with similar performances.
dc.description.abstractConclusion: Thresholds of non-invasive fibrosis scores (Hepamet, FIB-4 and NFS) can be modified to maximize diagnostic accuracy in Latin American patients with NAFLD. (C) 2020 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espafia, S.L.U.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.aohep.2020.08.066
dc.identifier.issn1665-2681
dc.identifier.urihttps://doi.org/10.1016/j.aohep.2020.08.066
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/100343
dc.identifier.wosidWOS:000585342300009
dc.issue.numero6
dc.language.isoen
dc.pagina.final626
dc.pagina.inicio622
dc.revistaAnnals of hepatology
dc.rightsacceso restringido
dc.subjectNonalcoholic fatty liver disease
dc.subjectFibrosis
dc.subjectHepamet fibrosis score
dc.subjectFibrosis-4 (FIB-4)
dc.subjectNAFLD fibrosis score (NFS)
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDiagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population
dc.typeartículo
dc.volumen19
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas